Keros Therapeutics Inc held its 2025 Annual Meeting of Stockholders on June 9, 2025. During the meeting, stockholders expressed significant concern about the Board's capital allocation decisions. Proposals included a call for the company to return $475 million to stockholders through a special dividend by the end of Q3 2025, which was not approved. Additionally, there was a proposal for implementing a contingent value right related to the Takeda partnership by year-end, which was also not approved. Significant withhold votes were recorded against directors Mary Ann Gray and Alpna Seth, reflecting a demand for change and a more disciplined capital allocation strategy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY06322) on June 09, 2025, and is solely responsible for the information contained therein.